409 related articles for article (PubMed ID: 6424339)
61. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
Keularts IM; Hamulyak K; Hemker HC; Béguin S
Thromb Haemost; 2000 Oct; 84(4):638-42. PubMed ID: 11057863
[TBL] [Abstract][Full Text] [Related]
62. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.
Lethagen S; Harris AS; Nilsson IM
Blut; 1990 Mar; 60(3):187-91. PubMed ID: 2107887
[TBL] [Abstract][Full Text] [Related]
63. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease.
Casonato A; Pontara E; Dannhaeuser D; Bertomoro A; Sartori MT; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):959-64. PubMed ID: 7893933
[TBL] [Abstract][Full Text] [Related]
64. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
[TBL] [Abstract][Full Text] [Related]
65. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
66. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
Lethagen S
Semin Thromb Hemost; 2003 Feb; 29(1):101-6. PubMed ID: 12640572
[TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
[TBL] [Abstract][Full Text] [Related]
68. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
[TBL] [Abstract][Full Text] [Related]
69. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
[TBL] [Abstract][Full Text] [Related]
70. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.
Rodeghiero F; Castaman G; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):692-6. PubMed ID: 8950775
[TBL] [Abstract][Full Text] [Related]
71. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
72. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
Warrier AI; Lusher JM
J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
[TBL] [Abstract][Full Text] [Related]
73. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
74. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin.
de la Fuente B; Kasper CK; Rickles FR; Hoyer LW
Ann Intern Med; 1985 Jul; 103(1):6-14. PubMed ID: 3923887
[TBL] [Abstract][Full Text] [Related]
75. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease.
McKeown LP; Connaghan G; Wilson O; Hansmann K; Merryman P; Gralnick HR
Am J Hematol; 1996 Feb; 51(2):158-63. PubMed ID: 8579058
[TBL] [Abstract][Full Text] [Related]
76. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders.
Mörsdorf S; Köhler M; Leipnitz G; Wenzel E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962
[TBL] [Abstract][Full Text] [Related]
77. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
Fukui H; Takase T
Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
[No Abstract] [Full Text] [Related]
78. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.
Rodeghiero F; Castaman G; Di Bona E; Ruggeri M; Lombardi R; Mannucci PM
Eur J Haematol; 1988 Feb; 40(2):163-7. PubMed ID: 3126081
[TBL] [Abstract][Full Text] [Related]
79. [Prophylactic use of DDAVP in a patient with von Willebrand disease during labor: a case report and a review].
Miki T; Oh H; Hirasawa A; Morio S; Aotsuka N; Hiruma K; Wakita H; Endo N; Igarashi T; Asai T
Rinsho Ketsueki; 1990 Mar; 31(3):325-9. PubMed ID: 2366336
[TBL] [Abstract][Full Text] [Related]
80. [Clinical application of new synthetic vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP): hemostatic control of von Willebrand's disease (author's transl)].
Kobayashi I; Takahashi H; Sanada M; Takahashi K; Hattori A; Ito M; Sakuragawa N; Shibata A; Shinada S; Tsukada T
Rinsho Ketsueki; 1979 Apr; 20(4):364-71. PubMed ID: 312954
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
